Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will participate in two key investor conferences in June 2024: the Jefferies Global Healthcare Conference on June 6 and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12. The company will conduct fireside chats at both events, with audio webcasts available on their website. Jazz Pharmaceuticals focuses on developing medicines for serious diseases, including sleep disorders, epilepsy, and cancer. With headquarters in Dublin, Ireland, Jazz operates globally, driven by a patient-focused and science-driven approach.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that the FDA has granted Priority Review for zanidatamab, a HER2-targeted bispecific antibody, to treat HER2-positive metastatic biliary tract cancer (BTC). The target action date is set for November 29, 2024. If approved, zanidatamab will be the first HER2-targeted treatment for this condition. The submission is based on results from the Phase 2b HERIZON-BTC-01 trial, which showed a 41.3% confirmed objective response rate. Further data from this trial will be presented at the ASCO Annual Meeting 2024. Additionally, the Phase 3 HERIZON-BTC-302 trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy.
Jazz Pharmaceuticals announced a collaboration with Life Science Cares to enhance social impact via employee volunteerism in the U.S. This partnership aligns with Jazz's commitment to local communities where its employees reside. Life Science Cares leverages life sciences' financial and human capital to address poverty and inequality. The program will operate around Jazz's U.S. offices in Palo Alto, Philadelphia, and San Diego, encouraging employees to engage in meaningful volunteer activities. Jazz's Global Volunteer Day Policy allows employees to dedicate one paid workday annually to volunteer. Life Science Cares, active since 2016, has invested over $16 million and 55,000 volunteer hours to combat socio-economic disparities.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in the BofA Securities 2024 Global Health Care Conference on May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST. An audio webcast will be available via the Investors section of the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals plc is a global biopharma company focused on developing life-changing medicines for serious diseases. The company has a diverse portfolio of treatments for sleep disorders, epilepsy, and cancer. Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with a commitment to serving patients worldwide.
Jazz Pharmaceuticals reported a 12% year-over-year revenue increase driven by key growth drivers Xywav, Epidiolex, and Rylaze. They submitted zanidatamab BLA for 2L BTC, expect to launch in 2025, and affirmed 2024 total revenue guidance at $4.0 to $4.2 billion. Various pipeline catalysts and near-term data releases are anticipated. Financials showed a decrease in Xyrem net product sales, an increase in Epidiolex/Epidyolex net product sales, and Rylaze/Enrylaze net product sales. The company provided extensive updates on their key commercial products, pipeline highlights, financial highlights, and 2024 financial guidance.
Jazz Pharmaceuticals is focusing on taking actions to positively impact the planet during Earth Month. They are reflecting on steps to become more conscious of their actions and promoting sustainable practices. For more information, read their Corporate Sustainability and Social Impact Report.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
